| Autor: |
Baughn LB; a Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics , Mayo Clinic , Rochester , MN , USA., Sachs Z; b Division of Hematology, Oncology, and Transplantation, Department of Medicine , Minneapolis , MN , USA., Noble-Orcutt KE; b Division of Hematology, Oncology, and Transplantation, Department of Medicine , Minneapolis , MN , USA., Mitra A; c Genetics Cell Biology and Development, Division of Hematopathology, Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA., Van Ness BG; c Genetics Cell Biology and Development, Division of Hematopathology, Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA., Linden MA; d Division of Hematopathology, Department of Laboratory Medicine and Pathology , University of Minnesota , Minneapolis , MN , USA. |
| Abstrakt: |
Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3-4-fold. Here, we compared FBC and MC in the immunophenotypic characterization of Bz-sensitive and -resistant human MM cell line U266. We show that Bz-resistant cells are associated with the loss of CD56 and CD66a adhesion molecules as well as an activation signature. |
